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ieveral medical conditions that affect the cardio-
vascular system are restricted to or affect pre-
dominantly Africans. They can be considered
eglected diseases because, despite affecting consider-
ble numbers of people, they have not been the sub-
ect of systematic research or structured control pro-
rams and did not benefit from translation of
nowledge obtained in other areas of human knowl-
dge. Their epidemiology and natural history are of-
en incompletely described, and the etiology and
athogenesis are unclear, leading to little or no im-
rovement in medical care for patients, and absence
f effective preventive measures for their control.
pidemiology
he epidemiology of cardiovascular diseases in Africa,
eported mainly on hospitalized patients, may not
epresent the true pattern of heart disease in the conti-
ent but suggests a high burden of neglected condi-
ions such as rheumatic valve disease, cardiomyopa-
hies, and tuberculous pericarditis (Table 1) (1–6).
he significance of these cardiac diseases is often un-
ppreciated or dwarfed by diseases such as malaria,
cute respiratory infections, water-borne diseases, tu-
erculosis, and acquired immunodeficiency syndrome
AIDS), which are major public health problems in
frica. However, they impose a major burden upon
he patients, the families, the health systems, and the
ocieties as a whole.
Two large-scale community studies looking at the
revalence of rheumatic heart disease (RHD) and
ndomyocardial fibrosis (EMF) in Mozambique con-
rmed both conditions as major public health prob-
ems in this country and highlighted the need for local
esearch on neglected diseases. The first survey, using
linical and echocardiographic screening, studied a,370 children ages 6 to 17 years who were randomly
elected from 6 primary schools and revealed a preva-
ence of RHD of 30.4 per 1,000 (95% confidence
nterval [CI]: 23.2 to 37.6) (7), which is more than
wice the highest previously reported number from a
urvey in schoolchildren from Kinshasa (14 per
,000) (8). The second study assessed a random sam-
le of 1,063 subjects of all ages selected through clus-
ering in a rural area with approximately 76,000 in-
abitants and found a prevalence of EMF of 19.8 
.4% (95% CI: 17.4% to 22.2%) (9).
Some conditions are almost confined to Africa, as
s the case for EMF and subvalvular aneurysms, while
thers can be found in other areas of the globe with
ifferent epidemiologies, such as RHD, peripartum
ardiomyopathy, and Takayasu arteritis. Finally, car-
iac manifestations of infectious diseases once con-
ned to Africa now have the potential to disseminate
orldwide due to increased traveling and the human
mmunodeficiency virus (HIV) pandemics.
HD. The waning burden of rheumatic fever/RHD
mong the 20% of the world’s population living
n high-income countries resulted in a decrease in
esearch and publications on the subject. However,
HD still is the most common form of acquired
ardiovascular disease in children and adolescents
n sub-Saharan Africa (10), where it is a major
ause of disability and premature death, and consti-
utes a serious problem in surviving adults, with a
eported prevalence of around 5.7 per 1,000 (11).
The exceptionally virulent forms of acute rheu-
atic fever commonly encountered in Africa affecting
hildren and adolescents (12,13) may be related to the
ost, the environment, or the streptococcus character-
stics. Supporting these hypotheses are the findings of
ntistreptolysin O titers over 200 reported in 37% of
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hildren below 10 years in an urban area of Nigeria (15),
nd in more than 29% of children ages 7 to 11 years in
hartoum (16).
Physicians in Africa face several challenges in dealing
ith rheumatic disease: patients present with complications
f chronic heart failure and cachexia, multiple valve surgery
nd tailored techniques are often required, and the decision
o operate includes not only clinical criteria but also the
apacity for adequate follow-up and compliance with sec-
ndary prophylaxis. The virulent nature of RHD in Africa
eads to a large number of patients needing surgery or inter-
entional catheterization, mainly for treatment of mitral
esions, but only few can benefit from this type of therapy.
he health care systems and the socioeconomic situation do
ot warrant the high level of care required to prevent re-
eated episodes of streptococcal pharyngitis, prevent recur-
ences of acute rheumatic heart fever, and deal with the
ssues related with surgery and anticoagulation. Therefore,
lthough there is a debate on the appropriateness of mitral
alve repair for patients with rheumatic disease in several
arts of the world (17–20), in Africa this is the most uti-
ized procedure due to the young age of patients and due to
ifficulties in follow-up of anticoagulation for those living
Table 1 Summary of Studies That Highlightof Neglected Heart Conditions in th
Authors (Ref. #) Country and
Sliwa et al. (6) South Africa, 1,593 of
January 1 to December
Cohort, tertiary hospita
Soliman and Juma (5) Malawi, 3,908 patients
January 2001 to Decem
Retrospective, tertiary h
Single cardiologist regi
Ansa et al. (2) Nigeria, 558 patients w
September 1996 to Se
Retrospective, tertiary h
Anthony (1) Nigeria, 315 patients w
January 1 to December
Prospective, tertiary ho
Hodes (3) Ethiopia 338 patients w
Retrospective, tertiary h
Freers et al. (4) Uganda 500 consecutiv
Echocardiography depa
Tertiary hospital
CHD  congenital heart disease; CMP  cardiomyopathy; CVD  c
PPCM  peripartum cardiomyopathy; RHD  rheumatic heart disease;n remote areas. bStructured national programs for prevention and control
f RHD do not exist in most African countries. The lack of
wareness from the health personnel is a major issue (21).
he lack of education of the general public, difficult acces-
ibility to the clinics, unaffordable costs of penicillin, and
ear of fatal penicillin allergy are also a problem. In this
ontext, implementing surgical programs in these poor set-
ings remains a big challenge. Local research into this con-
ition is crucial to allow the design of guidelines for its
iagnosis and management taking into account the unique
emographics and phenotypes found in these settings.
MF. EMF is the most common restrictive cardiomyopa-
hy worldwide (22), affecting primarily children from sub-
aharan Africa. Ethnicity, poverty, malnutrition, allergy
eosinophilia), dietary factors, infections, autoimmunity,
oxic agents, and heredity have been postulated as etiologi-
al factors (23–25), but the exact etiology and pathogenesis
emain unknown. Possible triggers are Plasmodium species
26), Schistosoma (27), Microfilaria (28), Helminths (25),
oxsackie B virus, arboviruses, and Toxoplasma gondhi (29).
utoimmunity may play a role (29,30). Familial clustering
ound in hospital- (31,32) and community-based studies
9) suggests genetic pre-disposition, but may also be caused
mportance
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Neglected Cardiovascular Diseases in Africa February 16, 2010:680–7Studies in Africa looking at EMF as being a variant of
he hypereosinophilic syndrome did not reach a conclusion.
lthough it was thought that parasitic infections would be
trigger for eosinophilia, their prevalence was not increased
n EMF patients compared with the general population
33,34). Eosinophilia has not been reported in the throm-
otic and fibrotic endocardial lesions studied in biopsies
35) and necropsy specimens (36). Moreover, degranulated
osinophils were absent in the blood and bone marrow
spirates of EMF patients, and no difference was found in
he mean concentrations of eosinophil granule basic pro-
eins in EMF patients and control subjects (34). However,
n inverse relationship of hypereosinophilia and duration
f the disease has been shown in initial stages of the
isease (25).
The natural history of EMF in Africa is incompletely
nderstood. Patients may recall signs of activity such as
rticaria or facial edema hypereosinophilia (25) but usually
resent in advanced stages of the disease with finger and toe
lubbing, growth retardation, testicular atrophy, failure to
evelop secondary sexual characteristics, and cachexia
37,38). In right-sided EMF, the most common form of
resentation, chronic systemic venous hypertension, leads
o exophthalmos, elevated jugular pressure, gross hepato-
egaly, congestive splenomegaly, and ascites with little or
o pedal edema (Fig. 1A). Even though cardiac cirrhosis
nd protein-losing enteropathy syndrome may play a role
n perpetuating it, its pathophysiology is not clear. The
ean survival time after diagnosis, initially reported at 2
ears (22), has been improving.
Although in endemic areas, the clinical presentation
eads to an easy diagnosis, echocardiography is important
or confirmation because it reveals the structural and hemo-
ynamic abnormalities that allow the differential diagnosis
ith conditions such as constrictive pericarditis, tubercu-
ous peritonitis, and intestinal schistosomiasis. Echocardi-
graphy shows increase in density and thickening of the
ndocardium, obliteration of the apices, valve dysfunction,
estrictive filling pattern, severe atrial enlargement, and
hrombi (Fig. 1B).
The medical treatment has poor results, and surgery
ust be done in all symptomatic cases. However, surgery is
echnically challenging and is rarely performed due to lack
f equipped facilities and late presentation of patients. A
esearch program has been applying tailored surgical tech-
iques with promising results (39). aeripartum cardiomyopathy. Peripartum cardiomyopa-
hy in Africa affects several thousand women, considering
he reported incidence in hospital-based studies, which
aries from 1 of 1,000 deliveries in South Africa (40) to 1
f 100 in Nigeria (41). This abnormally high incidence
ight be related to the prevalence of 2 major risk factors in
his population, namely black race and hypertension. Tra-
itional practices such as ingestion of food rich in Na and
eating of the body after delivery may also play a role (42).
African patients commonly present in severe heart failure
hat needs to be differentiated from dilated cardiomyopathy,
IV-related cardiomyopathy, pre-eclampsia, anemia, and
hiamine deficiency. In Africa, peripartum cardiomyopathy
Figure 1 Clinical and Echocardiographic
Features of Endomyocardial Fibrosis
(A) Giant ascites is characteristic of right-sided endomyocardial fibrosis. (B)
Echocardiography of left-sided endomyocardial fibrosis shows apical oblitera-
tion due to calcified thrombus, with left atrial dilation.ffects younger women who might therefore be at higher risk
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February 16, 2010:680–7 Neglected Cardiovascular Diseases in Africaf morbidity and mortality associated with recurrence, due to
ocial and cultural pressure to have several pregnancies.
Although the pathophysiology remains incompletely
nderstood, recent experimental and human data revealed
n unbalanced peripartum/post-partum oxidative stress,
inked to proteolytic cleavage of the nursing hormone pro-
actin into a potent antiangiogenic, proapoptotic, and
roinflammatory factor (43,44). Although it is a promising
herapeutic target, inhibition of prolactin secretion by bro-
ocriptine has yet to be disseminated into clinical practice.
ardiac manifestations of infectious diseases. Com-
unicable diseases, a public health problem in Africa, may
ffect the heart in various forms, a situation that has wors-
ned with the epidemics of HIV infection and AIDS. Par-
icularly tuberculosis and parasitic infections may produce a
ide spectrum of cardiac manifestations that express clini-
ally as myocarditis, pericarditis, cardiomyopathy, and/or
ulmonary hypertension.
UBERCULOUS PERICARDITIS. The true epidemiology
f tuberculous pericarditis in Africa is still unclear, but
he incidence is rising due to the epidemics of HIV/
IDS (45). Mycobacterium tuberculosis is responsible for
0% to 90% of large pericardial effusions (46) and cur-
ently accounts for up to 10% of all cases of congestive
eart failure in sub-Saharan Africa (47). Myopericardi-
is, pericardial effusion with or without tamponade,
ericardial constriction and effusive-constrictive pericar-
itis are commonly seen, sometimes associated with
ulmonary lesions (Fig. 2).
Echocardiography is not available in most health centers
n sub-Saharan Africa and, given the lack of technical ex-
ertise for pericardiocentesis and the difficulty in culturing
. tuberculosis, the diagnosis is usually late and based on
linical signs.
Preliminary data from a registry in Africa indicate
hat the disease is associated with an overall mortal-
ty of 26% at 6 months, rising to 40% in people with
IDS (48). This might be related to cardiac tampon-
de and constriction, which cannot be adequately
andled in many parts of the continent.
CHISTOSOMIASIS. Most countries with double infec-
ion of Schistosoma mansoni and haematobium are located
n the sub-Saharan region of Africa (49). Limited data
uggest that cardiopulmonary schistosomiasis is seen
ost often in S. mansoni infections, and that hepatic
brosis and portal hypertension are a prerequisite to the
evelopment of schistosomal cor pulmonale caused by shis species (50). Chronic accumulation of parasite eggs
n the lungs causes schistosoma-induced pulmonary hy-
ertension and cor pulmonale (51).
In endemic areas of Africa, the diagnosis is made
sually in young people on the basis of detection of
iable schistosomal ova in stool or urine in patients
ith pulmonary hypertension and chronic cor pulmo-
ale that cannot be attributed to any other recognizable
ause.
akayasu arteritis. Although epidemiological data on
akayasu arteritis in Africa are lacking, the condition is
requently seen in children causing renovascular hyperten-
ion (52), mainly in regions that are endemic for tuberculo-
Figure 2 Cardiopulmonary Changes
Associated With HIV and Tuberculosis
(A) Pulmonary and pericardial tuberculosis in a 35-year-old patient infected
with human immunodeficiency virus (HIV). (B) Echocardiography shows the
presence of intracardiac thrombus and myocardial masses obstructing both
the tricuspid valve and the right ventricular outflow tract.is (53–55). The diagnosis of Takayasu arteritis in Africa is
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Neglected Cardiovascular Diseases in Africa February 16, 2010:680–7hallenging due to unavailability of angiography, magnetic
esonance imaging, and computed tomography angiogra-
hy (Fig. 3). Regarding management of Takayasu arteritis,
teroids, immunosuppressive agents, cytotoxic drugs, and
otal lymphoid irradiation are used in the acute phase (55),
hereas surgery and/or interventional catheterization are
ndicated in chronic disease in centers where they are
vailable.
ubvalvular aneurysms. Subvalvular left ventricular an-
urysms are false aneurysms of unknown etiology that oc-
ur predominantly in black Africans (56), the most fre-
uent being submitral. They may produce symptoms in the
econd or third decade of life through diastolic overload,
itral regurgitation, thromboembolism, arrhythmias, or
ompression of the left circumflex artery and rupture into
he left atrium (57).
Patients may present sudden, acute, left-sided heart fail-
re with an insidious appearance of cardiac decompensa-
ion with angina. The examination typically shows an an-
urysmal pulsation in the third intercostal space with a
itral systolic murmur, and aneurysmal bulge on the left
ardiac border (56,58) on chest radiograph sometimes with
alcification of the rim of the ventricular opening of the
neurysm (58) and an abnormal electrocardiogram. Echo-
ardiography is the technique used for diagnosis following a
Figure 3 Aortography of Takayasu Disease Associated
With Severe Systemic Arterial Hypertension
Aortography of a 13-year-old girl with Takayasu Disease and systemic arte-
rial hypertension, showing severe aortic irregularities and complete left
renal artery occlusion.uspicious chest radiograph. lIn Africa, most patients are managed medically, and few
enefit from surgery that comports commonly pericardial
atch repair and valvuloplasty.
ardiovascular manifestations of Burkitt lymphoma
BL). BL, a highly aggressive B-cell neoplasm, is the most
ommon childhood malignancy in Africa (59,60). Epstein-
arr virus is clearly implicated by acting through deregula-
ion of the oncogene c-MYC by chromosomal transloca-
ion. Malaria, HIV, poverty, poor nutrition, and poor
ygienic conditions are other etiologic factors that may play
role (59,61), helping explain why the highest incidence
nd mortality rates are seen in Africa. Exposure to certain
lants (e.g., Euphorbiacae species) used traditionally in
any cultural activities, as well as to treat diarrhea and
ounds in tropical Africa, may act as cofactors in the
athogenesis of BL by enhancing the Epstein-Barr virus-
nduced transformation of human lymphocytes (61,62).
Burkitt lymphoma occurs in endemic areas for malaria
round the equatorial Africa. Although reduction of inci-
ence was achieved in areas where malaria was eradicated
63), an association between malaria and BL has never been
roven in population studies (61). Furthermore, BL occurs
ith higher frequency in individuals with HIV infection
64), explaining the rise in childhood prevalence in some
egions of Africa.
Cardiac manifestations of BL are intracardiac masses
ith pericardial effusion, right heart failure, or acute pul-
onary embolism. Unavailability of diagnostic and man-
gement tools in most endemic areas in Africa explains the
oor prognosis.
urrent Challenges and
ew Opportunities for Africa
he epidemiology of cardiovascular diseases in Africa dif-
ers across certain groups of the population, probably due
o different exposure to known and unknown risk factors,
nhealthy lifestyles, access to health care, and environmen-
al conditions, including traditional customs. Diseases
inked to poverty and famine are still highly prevalent.
ealth infrastructures adequately equipped for diagnosis
nd care are lacking, and there is an absence of research
o deliver the required scientific advances in a reasonable
imescale (6,64). At the same time, chronic cardiovascu-
ar conditions emerge linked to rapid urbanization, lack
o
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February 16, 2010:680–7 Neglected Cardiovascular Diseases in Africaf physical activity, obesity, hypertension, high-salt and
igh-cholesterol content diets, tobacco, diabetes, and
ncrease in life expectancy (5,65).
A major challenge for Africa is to increase knowledge on
pidemiology and pathogenesis of neglected conditions to
llow improvements in management and prevention. How-
ver, research-funding sources are rare because there are few
ndustries and trusts. For economic and political reasons,
here has been considerable brain drainage, and when fund-
ng is available, there is lack of expertise to administer re-
earch projects. On the other hand, policymakers are con-
erned that investment in research into the conditions will
nterfere with efforts to control communicable diseases.
The geographical distribution of some neglected diseases
ight be related to traditional customs and local practices
trictly adhered to by certain communities or to plants used
n certain communities by traditional healers in their activ-
ty that might act as toxins (42,66). Therefore, understand-
ng the role of these practices as etiological factors or deter-
inants of neglected diseases is needed.
The African cardiovascular community has recognized
he need for an appropriate research agenda for neglected
ardiovascular diseases, and several actions have been taken:
) the Drakensberg declaration on the control of rheumatic
ever and rheumatic heart disease in Africa (67); 2) the con-
titution of the Pan African Society of Cardiology an um-
rella organization for all health professionals working on
ardiovascular diseases; 3) the pilot trial of adjunctive pred-
isone and Mycobacterium w immunotherapy in tubercu-
ous pericarditis involving several countries in Southern
frica; 4) the Heart of Soweto Project studying the epidemi-
logical transition and neglected diseases such as peripar-
um cardiomyopathy in South Africa (6); and 5) the re-
earch program on EMF in Mozambique (68).
The implementation of such research programs involves
commitment of local researchers, who have been able to
ttract international collaboration and funding from the
estern world. Initiatives such as the WHO Programme
or Research and Training in Tropical Diseases and the
rugs for Neglected Diseases Initiative may also be used
69). These initiatives will hopefully increase awareness of
ocal governments and the international scientific commu-
ity regarding the burden of neglected cardiovascular dis-
ases, as well as stimulate the retention of high-quality local
ealth personnel and researchers.onclusions
ultidisciplinary strategies may be used to increase re-
earch aimed at improving knowledge of epidemiology,
echanisms, and management of neglected cardiovascular
iseases. Such strategies should include: 1) building re-
earch capacity in health sciences in Africa through North-
outh collaboration projects led by local investigators;
) designing projects that involve collaboration between
frican institutions; 3) prioritizing research into these mo-
ecular mechanisms of cardiovascular diseases that are
nique to Africa; 4) evolving innovative management strat-
gies tailored to the African setting; and 5) understanding
he scientific and lay aspects of traditional medicine that
ight have implications in the health status of the commu-
ities.
Nongovernmental organizations and health professional
ssociations in Africa must be the stakeholders in the pro-
ess of acquiring accurate data on the burden of neglected
ardiovascular conditions in Africa in order to advocate
hanges in health policies and priorities for research in the
ontinent.
eprint requests and correspondence: Dr. Ana Olga H. Moc-
mbi, Instituto do Coração, Av Kenneth Kaunda 1111, Maputo,
ozambique. E-mail: amocumbi@yahoo.com or amocumbi@
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